Evaluation of tedizolid against<i>Staphylococcus aureus</i>and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid

Abstract

Tedizolid MICs demonstrate activity against isolates with decreased susceptibility to alternative agents, including linezolid. Tedizolid may be a viable treatment option in clinical situations with MDR Gram-positive pathogens.